PRODUCT INFORMATION

Roxatidine-d_{10} (hemioxalate)

Item No. 34007

CAS Registry No.: 2832423-41-1
Formal Name: 2-hydroxy-N-[3-[3-(1-piperidinyl-2,2,3,3,4,4,5,5,6,6-d_{10}-methyl)phenoxy] propyl]-acetamide, ethanedioate (2:1)
MF: $C_{17}H_{16}D_{10}N_2O_3 \bullet 1/2C_2H_2O_4$
FW: 361.5
Chemical Purity: ≥95% (Roxatidine)
Deuterium Incorporation: ≥99% deuterated forms (d_1-d_{10}); ≤1% d_0
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Roxatidine-d_{10} (hemioxalate) is intended for use as an internal standard for the quantification of roxatidine by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated *versus* unlabeled).

Roxatidine-d_{10} (hemioxalate) is supplied as a solid. A stock solution may be made by dissolving the roxatidine-d_{10} (hemioxalate) in the solvent of choice, which should be purged with an inert gas. Roxatidine-d_{10} (hemioxalate) is soluble in DMSO.

Description

Roxatidine is a histamine H_2 receptor antagonist and major active metabolite of roxatidine acetate (Item No. 21248).[1] Roxatidine reduces histamine-induced adenylate cyclase production in guinea pig parietal cells (IC_{50} = 0.8 µM). It inhibits histamine-induced hydrogen ion accumulation in the same cells (pA_2 = 7.03). Roxatidine (200 mg/kg) reduces small intestinal lesion area in a rat model of gastric mucosal injury induced by indomethacin (Item No. 70270).[2]

References

1. Sewing, K.-F., Beil, W., and Hannemann, H. Comparative pharmacology of histamine H_2-receptor antagonists. *Drugs* **35(Suppl. 3)**, 25-29 (1988).
2. Umegaki, E., Yoda, Y., Tokioka, S., *et al*. Protective effect of roxatidine against indomethacininduced small intestinal mucosal injury in rats. *J. Gastroenterol. Hepatol.* **25(Suppl. 1)**, S35-S40 (2010).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM